Conference report: post hoc analysis from phase III ASCLEPIOS I and II trials of ofatumumab in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

Post hoc analysis (n=615) in a subgroup of patients with early disease (median age and MS duration since diagnosis of 36 and 0.35 years, respectively) showed that ofatumumab reduced annualised relapse rate by 50.3% (0.09 vs 0.18) vs. teriflunomide (p<0.001).


Biospace Inc.